Notification of Site Visit

Hikma Pharmaceuticals Plc
20 November 2006

                            NOTIFICATION OF SITE VISIT

London, 20 November 2006 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK), the
multinational pharmaceuticals group, is hosting a site visit in Sintra, Portugal
today.

Hikma will provide an overview of its core businesses as well as a tour of its
Injectable manufacturing facilities, which include the new state-of-the-art
cephalosporin plant.

No material new information will be disclosed and there will not be any further
statement on current trading. Copies of today's presentations will be posted on
the company's website, www.hikma.com.

                                    - ENDS -

Enquiries:
Hikma Pharmaceuticals PLC

Susan Ringdal                                            [phone]
Investor Relations Director

Brunswick Group
Jon Coles / Justine McIlroy / Alex Tweed                 [phone]

About Hikma

Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: Generic, Branded and Injectable
Pharmaceuticals. Hikma's operations are based principally in the United States,
the Middle East and North Africa ('MENA') region and Europe. In 2005, the Group
had revenue of $262 million and profit attributable to shareholders of $44
million. At 31 December 2005, the Group had over 1,800 employees. For news and
other information, please visit www.hikma.com.






                      This information is provided by RNS
            The company news service from the London Stock Exchange